EliLilly

Eli Lilly’s Next‑Gen Obesity Pill Shows Promise for Sleep Apnea and More

The GLP-1 Revolution: WeightWatchers Embraces New Era, Eli Lilly Expands Horizons

A New Chapter for Weight Loss: WW Leans into GLP-1s as Eli Lilly Explores Wider Medical Miracles

Medicare’s $50 GLP‑1 Weight‑Loss Plan: What the Numbers Really Mean

Medicare’s $50 Weight‑Loss Drug Plan: What the Numbers Really Mean

A Single Shot to Revolutionize Heart Health? Eli Lilly's Gene-Editing Breakthrough

The Future of Immunity: Eli Lilly's Bold Strategic Play in Vaccine Development

Chamath Palihapitiya Joins Forces with Eli Lilly to Target LDL Cholesterol with Gene‑Editing Therapy

The Weight Loss Revolution: Eli Lilly Unveils a New Horizon

The Next Frontier in Weight Loss: Eli Lilly's Latest Innovation

The Eli Lilly Rollercoaster: Deciphering a Volatile Week in the Market

A New Frontier in Medicine: AI and Pharma Unite for Groundbreaking Drug Discovery

Eli Lilly's Cancer Revolution: How Loxo Oncology Reshaped an Empire

Deepening Roots: India's Manufacturing Dreams and Global Pharma's Embrace

Eli Lilly's Retatrutide Triumphs in Key Diabetes Trial, Poised to Reshape Obesity Treatment Landscape

Five Crucial Stocks to Watch as We Kick Off the Trading Week

Global Markets Wobble: Asian Shares Reflect Wall Street's AI Stock Rollercoaster

The Final Word: Navigating Pharma's Powerhouse and Gold's Gleam in Today's Markets

Huntsville's Bold Bet: Unpacking the Multi-Billion-Dollar Eli Lilly Investment

Wegovy in Vials? Novo Nordisk's Strategic Shift to Boost Supply and Challenge Eli Lilly

The Weight-Loss Drug Wars: Novo Nordisk Eyes Vials for Wegovy in High-Stakes Battle

GLP-1 Medications: Separating Hype from Health with Expert Insights

Hims & Hers Hits the Brakes: Generic Wegovy Plans Abandoned Amidst GLP-1 Market Shifts

Eli Lilly's Ascendant Journey: Why Its Premium Price Tag Might Just Be Worth It

Novo Nordisk: The High-Stakes Balancing Act Between Price and Scale

The Market's Two Minds: Lilly's High-Stakes Game Meets Housing's Quiet Comeback

Eli Lilly CEO Sees Medicare Support as Game-Changer for New Oral Obesity Pill

The Pharmaceutical Frontier: Navigating Breakthroughs, Billions, and Bitter Debates

Navigating the Complex Currents of Modern Pharmaceuticals

A $6 Billion Bet on Indiana: Eli Lilly's Massive Expansion Promises Thousands of Jobs

A Collective Sigh of Relief: Eli Lilly Breaks Nine-Day Losing Streak

The Great Unbundling: Why Weight Loss Drug Prices Are Finally Coming Down

Eli Lilly's Jaypirca Secures Full FDA Approval, Offering New Hope for Certain Blood Cancers

Eli Lilly's Zepbound Gets a Significant Price Drop: What It Means for Patients and the Market

The Great Pharma Race: GLP-1s, Billions, and the Battle for What's Next

Eli Lilly Slashes Zepbound Prices Amid Political Pressure and Trump's Claims

The Next Frontier: Unpacking 'Ozempic 2.0' and the Future of Weight Management

Unanimous Picks: Why Top Funds Are Doubling Down on These Six Stocks

A New Era for Weight Loss: The Revolution of GLP-1 Pills and Monthly Shots